TransMedics Group (TMDX) Competitors $116.88 +4.42 (+3.93%) Closing price 07/14/2025 04:00 PM EasternExtended Trading$117.40 +0.52 (+0.44%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TMDX vs. SOLV, SNN, PEN, STVN, GKOS, BLCO, NARI, IRTC, SLNO, and INSPShould you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inari Medical (NARI), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. TransMedics Group vs. Its Competitors Solventum Smith & Nephew SNATS Penumbra Stevanato Group Glaukos Bausch + Lomb Inari Medical iRhythm Technologies Soleno Therapeutics Inspire Medical Systems Solventum (NYSE:SOLV) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Does the media prefer SOLV or TMDX? In the previous week, TransMedics Group had 11 more articles in the media than Solventum. MarketBeat recorded 16 mentions for TransMedics Group and 5 mentions for Solventum. TransMedics Group's average media sentiment score of 1.24 beat Solventum's score of 0.61 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SOLV or TMDX? Solventum has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Do analysts recommend SOLV or TMDX? Solventum presently has a consensus price target of $81.50, suggesting a potential upside of 10.01%. TransMedics Group has a consensus price target of $125.13, suggesting a potential upside of 7.05%. Given Solventum's higher probable upside, analysts clearly believe Solventum is more favorable than TransMedics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18TransMedics Group 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Is SOLV or TMDX more profitable? TransMedics Group has a net margin of 10.03% compared to Solventum's net margin of 4.55%. Solventum's return on equity of 31.01% beat TransMedics Group's return on equity.Company Net Margins Return on Equity Return on Assets Solventum4.55% 31.01% 6.53% TransMedics Group 10.03%21.88%6.15% Which has better earnings and valuation, SOLV or TMDX? Solventum has higher revenue and earnings than TransMedics Group. Solventum is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolventum$8.25B1.55$478M$2.1634.30TransMedics Group$441.54M8.95$35.46M$1.3685.94 Do insiders and institutionals have more ownership in SOLV or TMDX? 99.7% of TransMedics Group shares are held by institutional investors. 0.1% of Solventum shares are held by company insiders. Comparatively, 7.0% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryTransMedics Group beats Solventum on 11 of the 17 factors compared between the two stocks. Get TransMedics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TMDX vs. The Competition Export to ExcelMetricTransMedics GroupMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.95B$6.68B$5.54B$9.14BDividend YieldN/A1.28%5.01%4.00%P/E Ratio85.9426.3428.6919.45Price / Sales8.9564.17372.4779.78Price / Cash68.3520.6824.7227.47Price / Book17.164.728.215.58Net Income$35.46M$174.76M$3.19B$252.81M7 Day Performance-6.29%-1.13%3.60%2.11%1 Month Performance-18.20%2.07%9.61%11.87%1 Year Performance-19.03%6.92%30.04%16.61% TransMedics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TMDXTransMedics Group1.4641 of 5 stars$116.88+3.9%$125.13+7.1%-17.8%$3.95B$441.54M85.94210Positive NewsSOLVSolventum0.616 of 5 stars$76.24-2.9%$81.50+6.9%+51.2%$13.19B$8.25B35.3022,000SNNSmith & Nephew SNATS3.0332 of 5 stars$29.95-1.1%$28.00-6.5%+5.8%$13.12B$5.81B13.8717,349PENPenumbra4.7691 of 5 stars$248.05-1.2%$302.40+21.9%+25.2%$9.61B$1.19B234.014,500STVNStevanato Group1.4461 of 5 stars€24.23-1.5%N/A+17.7%€7.34B€1.19B47.515,521Positive NewsGKOSGlaukos4.3524 of 5 stars$101.69-1.7%$134.67+32.4%-13.8%$5.81B$383.48M-42.91780BLCOBausch + Lomb3.0508 of 5 stars$13.83-0.4%$15.54+12.4%-14.3%$4.89B$4.79B-13.4313,500NARIInari Medical0.276 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800IRTCiRhythm Technologies1.0471 of 5 stars$139.22-2.3%$138.60-0.4%+44.4%$4.44B$591.84M-44.342,000SLNOSoleno Therapeutics4.6066 of 5 stars$85.27-1.6%$107.10+25.6%+73.6%$4.30BN/A-18.4630INSPInspire Medical Systems4.8827 of 5 stars$127.11-1.1%$211.91+66.7%-6.3%$3.75B$802.80M58.581,246Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies Solventum Alternatives Smith & Nephew SNATS Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Bausch + Lomb Alternatives Inari Medical Alternatives iRhythm Technologies Alternatives Soleno Therapeutics Alternatives Inspire Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TMDX) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
